Neuraxis (NRXS) Research & Development (2022 - 2025)
Neuraxis (NRXS) posted Research & Development of $146178.0 for Q4 2025, up 9548.71% sequentially from $1515.0 in Q3 2025, and up 5.6% YoY from $138426.0 in Q4 2024.
Neuraxis (NRXS) Research & Development (2022 - 2025) Analysis & Trends
Neuraxis has reported Research & Development for 4 years, with the latest figure at $146178.0 in Q4 2025.
- Quarterly Research & Development rose 5.6% year-over-year to $146178.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $207969.0 (up 43.45% YoY) and the FY2025 annual result came in at $493611.0, up 13.84% from the prior year.
- Research & Development climbed to $146178.0 in Q4 2025 per NRXS's latest filing, from $1515.0 in the prior quarter.
- Over five years, Research & Development peaked at $146178.0 in Q4 2025 and troughed at -$2221.0 in Q4 2023.
- A 4-year average of $50247.8 and a median of $30873.5 in 2023 frame the typical range for Research & Development.
- The sharpest annual moves came in 2023 and 2024: Research & Development plunged 102.73% in 2023, then surged 6332.6% in 2024.
- Over 4 years, Research & Development stood at $81371.0 in 2022, then plunged by 102.73% to -$2221.0 in 2023, then soared by 6332.6% to $138426.0 in 2024, then rose by 5.6% to $146178.0 in 2025.
- According to Business Quant data, Research & Development over the past three periods registered $146178.0, $1515.0, and $58319.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Neuraxis | 75.51 Mn | 67.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 146,178.00 |
| Sep 30, 2025 | 1,515.00 |
| Jun 30, 2025 | 58,319.00 |
| Mar 31, 2025 | 1,957.00 |
| Dec 31, 2024 | 138,426.00 |
| Jun 30, 2024 | 978.00 |
| Mar 31, 2024 | 5,570.00 |
| Dec 31, 2023 | -2,221.00 |
| Sep 30, 2023 | 44,950.00 |
| Jun 30, 2023 | 109,789.00 |
| Mar 31, 2023 | 16,797.00 |
| Dec 31, 2022 | 81,371.00 |
| Sep 30, 2022 | 86,175.00 |
| Jun 30, 2022 | 13,665.00 |